Rheumatology News

Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity and remission, and more time spent in those states, vs. standard therapy alone, according to data.

The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press release from Johnson & Johnson.

A 5-year study of bimekizumab in ankylosing spondylitis encountered no new safety signals, with efficacy sustained even in a conservative analysis with non-responder imputation, according to data published in RMD Open.

Patients with osteoarthritis, but not immune-related arthritis, demonstrate increased odds for developing overactive bladder vs. those without, according to data spanning 15 years published in Science Reports.

Filgotinib, a Janus Kinase 1 inhibitor, remains well-tolerated for up to 8 years with consistent efficacy in patients with rheumatoid arthritis, according to data published in RMD Open.

Developing myalgic encephalomyelitis/chronic fatigue syndrome is significantly more likely after a case of COVID-19, an important connection for rheumatologists as they sort through symptoms and medical histories for a diagnosis, data show.

Systemic sclerosis appears to have a “non-random” occurrence across the United States, with clusters of people diagnosed around environmentally contaminated Superfund sites, according to data published in Arthritis Care & Research.

Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has several limitations that may be overcome instead through bispecific T-cell-engaging antibodies, according to a speaker.

A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the long-term, drug-free remission from autoimmune diseases observed after treatment, according to a speaker.